Mounjaro prescribing runs through a fixed sequence of six strengths, starting at 2.5mg and stepping through 5mg, 7.5mg, 10mg, and 12.5mg before reaching the 15mg ceiling, with each stage requiring prescriber confirmation that the prior dose was tolerated before the next is authorised. No strength sits outside this sequence and none is entered without that confirmation. The mounjaro click chart maps each strength to its exact pen setting, giving patients a stage-by-stage reference for the click position that matches the prescribed dose. Every patient begins at 2.5mg regardless of diagnosis or weight status. That opening stage runs for a minimum of four weeks before any upward move is reviewed. The four-week minimum applies at each stage because the body needs time at each concentration before the next is introduced. Strength selection at every point in the plan is tied to what the clinical review at that stage shows, not to elapsed time alone.

Does every patient reach 15mg?

No, not every patient is prescribed the 15mg dose. The plan stops at the strength where weight response is adequate and the dose is well tolerated, which for many patients falls below the ceiling level. A patient recording consistent weight loss at 7.5mg or 10mg has no clinical reason to escalate further.

  • Response assessment at each stage – Prescribers review weight data, side effect profile, and tolerance before deciding whether the next strength is appropriate or whether the current dose should be held.
  • Ceiling dose as boundary – The 15mg strength marks the upper limit of the plan, not a target every patient is directed toward. Reaching it depends entirely on what prior stages have shown.
  • Held dose scenarios – Where a patient responds well at a mid-range strength, the prescriber may hold that dose for the remainder of the plan without any further escalation.

Stage strengths in order

The six strengths within the Mounjaro plan follow a set order that does not change regardless of the patient’s starting profile. 2.5mg opens the plan for all patients and sits at that level for four weeks minimum. 5mg follows where tolerance at the opening stage is confirmed. 7.5mg is the first point where some patients reach their clinical response target and escalation stops. 10mg is prescribed where the mid-range strength has not produced the response the prescriber is looking for after the required exposure period. 12.5mg sits one stage below the ceiling and is used where 10mg has run its course without sufficient progress. 15mg closes the sequence for patients who have moved through each prior stage without reaching the clinical target at a lower strength.

Pen settings confirm each dose

Each strength requires a different pen setting, and the click count for that setting changes at every stage.

  • 2.5mg setting – The lowest click count on the pen, used only at the opening stage and not carried forward once the plan progresses to 5mg.
  • Mid-range settings – Each strength between 5mg and 12.5mg has its own click count that must be set fresh at the start of each new stage rather than estimated from the previous position.
  • 15mg setting – The highest click count on the pen, used only where the prescriber has authorised progression to the ceiling dose after reviewing clinical data from the prior stage.

Checking the pen setting against the prescribed stage before each injection keeps the delivered dose consistent with what the prescriber has authorised at that point in the plan.